BFRI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

15.54M

+23.72%

0.100

-143.1%

9.10M

+5.96%

-0.180

-64.59%

10.00M

+10.74%

-0.120

-78.79%

Estimates Revision

The market is revising Downward the revenue expectations for Biofrontera Inc. (BFRI) for FY2025, with the revenue forecasts being adjusted by -1.23% over the past three months. During the same period, the stock price has changed by -9.28%.

Revenue Estimates for FY2025

Revise Downward

-1.23%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-9.28%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast BFRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BFRI is 6.00 USD with a low forecast of 3.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.790

Low

3.00

Averages

6.00

High

9.00

Current: 0.790

Low

3.00

Averages

6.00

High

9.00

Roth Capital

Buy

upgrade

$8 -> $10

2025-06-30

Reason

Roth Capital

Price Target

$8 -> $10

2025-06-30

upgrade

Buy

Reason

Roth Capital raised the firm's price target on Biofrontera Inc. to $10 from $8 and keeps a Buy rating on the shares. The firm notes Biofrontera Inc. acquired full U.S. Ameluz and RhodoLED rights from former parent company Biofrontera AG, which, when combined with the $11M investment from existing institutional investors, funds Biofrontera Inc. to profitability.

Benchmark

Bruce Jackson

Buy

downgrade

2025-05-19

Reason

Benchmark

Bruce Jackson

Price Target

2025-05-19

downgrade

Buy

Reason

Valuation Metrics

The current forward P/E ratio for Biofrontera Inc (BFRI.O) is -1.88, compared to its 5-year average forward P/E of -12.65. For a more detailed relative valuation and DCF analysis to assess Biofrontera Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.65

Current PE

-1.88

Overvalued PE

33.22

Undervalued PE

-58.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.10

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.27

Undervalued EV/EBITDA

-0.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.58

Current PS

0.00

Overvalued PS

1.30

Undervalued PS

-0.14

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BFRI News & Events

Events Timeline

No data

News

9.0

12-04Newsfilter

Biofrontera Completes Phase 1 Study of Ameluz®; Plans FDA Submission for 2026

9.5

11-13Newsfilter

Biofrontera Inc. Announces Financial Results for Q3 2025 and Offers Business Update

7.5

11-07Benzinga

EXCLUSIVE: Pelthos Acquires Antimicrobial Drug Rights and Raises $18 Million for Commercial Launch Support

People Also Watch

Frequently Asked Questions

What is Biofrontera Inc (BFRI) stock price today?

The current price of BFRI is 0.79 USD — it has decreased -2.71 % in the last trading day.

What is Biofrontera Inc (BFRI)'s business?

Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.

What is the price predicton of BFRI Stock?

What is Biofrontera Inc (BFRI)'s revenue for the last quarter?

Biofrontera Inc revenue for the last quarter amounts to 6.99M USD, decreased -22.46 % YoY.

What is Biofrontera Inc (BFRI)'s earnings per share (EPS) for the last quarter?

Biofrontera Inc. EPS for the last quarter amounts to -0.62 USD, decreased -36.73 % YoY.

What changes have occurred in the market's expectations for Biofrontera Inc (BFRI)'s fundamentals?

How many employees does Biofrontera Inc (BFRI). have?

Biofrontera Inc (BFRI) has 92 emplpoyees as of December 16 2025.

What is Biofrontera Inc (BFRI) market cap?

Today BFRI has the market capitalization of 9.20M USD.